A Role of Multilevel Healthcare Access Dimensions in Ovarian Cancer Disparities
多层次医疗保健获取维度在卵巢癌差异中的作用
基本信息
- 批准号:10394858
- 负责人:
- 金额:$ 49.46万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-02-01 至 2024-04-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvantAftercareAmericanAreaAttitudeBlack raceCancer PatientCancer SurvivorCaringCommunity SurveysComplexCost SharingDataData SetDatabasesDevelopmentDimensionsEquationFatigueFinancial HardshipGuidelinesHealth PersonnelHealth Services AccessibilityHealthcareHospitalsKnowledgeLinkLocationMalignant NeoplasmsMalignant neoplasm of ovaryMediatingMedicareMental DepressionModelingNational Cancer InstituteNatureNeighborhoodsOperative Surgical ProceduresOutcomePainPatient Outcomes AssessmentsPatientsPatterns of CarePerceptionPharmaceutical PreparationsPlatinumPopulationPovertyProviderQuality of CareQuality of lifeRaceReportingResearch PersonnelResourcesRoleRuralSEER ProgramSamplingSocial supportSourceSpecialistSubgroupSupportive careSurveysSurvival RateSurvivorsSymptomsTimeTravelTrustTumor DebulkingWomanbarrier to carebaseblack patientblack womencancer carecancer health disparitycancer survivalcancer therapychemotherapycohortdifferences in accessdisparity reductionhealth care availabilityhealth care servicehealth care service organizationhealth literacyhealthcare acceptabilityimprovedinsightneoplasm registrynovelpatient-clinician communicationpopulation basedpreferenceracial differenceracial disparityrecruitsocioeconomicssurveillance datasymptom managementtheoriestreatment strategytrend
项目摘要
Less than 40% of ovarian cancer (OC) patients in the US receive stage-appropriate guideline- adherent
surgery and chemotherapy; Black OC patients are even less likely to receive such treatment. While 5-year
relative survival for White OC patients improved by 47% between 1975 and 2009, it declined by 27% for
Black patients during this same period. Among cancer survivors, Black patients are also observed to have
significantly higher depression, pain, and fatigue than White survivors. These racial disparities are likely due
largely to differences in healthcare access – specifically, access to high quality initial treatment and post-
treatment supportive care. Healthcare access is a complex subject; however, the Penchansky healthcare
access framework proposed that it comprises of five specific dimensions: availability, affordability,
accessibility, accommodation and acceptability of health care services. Our study will comprehensively
evaluate all five dimensions of healthcare access (HCA) among Black and White patients to identify and
quantify the specific factors contributing to the striking racial differences in OC care and survival. More
specifically, we will utilize data from SEER-Medicare (8,060 OC patients) along with primary survey data
from a population-based sample of 1,010 OC patients, linked with several existing datasets (e.g., American
Community Survey, Area Healthcare Resource File), to characterize racial differences in associations
between each HCA dimension and three outcomes: quality of initial treatment and supportive care, quality of
life based on patient-reported outcomes in prevalent yet manageable symptoms, and survival. We will
evaluate HCA dimensions across patient, neighborhood, provider and hospital levels, and utilize hierarchical
regression models with random effects to account for clustering, and multilevel structural equation models to
estimate the total, direct and indirect effect of race on treatment mediated through HCA dimensions. Our
preliminary studies suggest that certain under-studied dimensions (e.g., acceptability) may outweigh other
dimensions (e.g., availability) in determining quality of care. Moreover, the impact of the various HCA
dimensions may vary by race. By analyzing high-quality multilevel datasets with Black and White patients,
we can fully characterize the nature of racial disparities, assess the relative importance of race-specific
barriers to care, and identify race-specific modifiable factors. Our study will provide novel, empirical, and
generalizable insights regarding the distinct and collective influence of HCA dimensions on OC outcomes.
These insights will help identify and prioritize specific modifiable factors that can then be targeted to reduce
disparities and improve care for all patients.
在美国,不到40%的卵巢癌(OC)患者接受了符合分期指南的治疗。
手术和化疗;黑OC患者更不可能接受这种治疗。虽然5年
1975年至2009年,白色OC患者的相对生存率提高了47%,
在同一时期的黑人患者。在癌症幸存者中,也观察到黑人患者
与白色幸存者相比,抑郁、疼痛和疲劳显著更高。这些种族差异可能是由于
这主要是由于医疗保健获得方面的差异----特别是获得高质量的初始治疗和治疗后的差异----
治疗支持护理。获得医疗保健是一个复杂的问题;然而,Penchansky医疗保健
获得框架建议,它包括五个具体方面:可获得性,可负担性,
保健服务的可获得性、便利性和可接受性。我们的研究将全面
评估黑人和白色患者的医疗保健获取(HCA)的所有五个维度,以识别和
量化导致OC护理和生存率显着种族差异的具体因素。更
具体而言,我们将利用来自SEER医疗保险(8,060名OC患者)的数据以及主要调查数据沿着
来自1,010名OC患者的基于人群的样本,与几个现有的数据集(例如,美国
社区调查,地区医疗保健资源文件),以描述相关性中的种族差异
每个HCA维度与三个结果之间的关系:初始治疗和支持性护理的质量,
根据患者报告的流行但可管理的症状和生存率的结果确定寿命。我们将
评估HCA在患者、社区、提供者和医院层面的维度,并利用分层
用随机效应回归模型来解释聚类,用多级结构方程模型来解释聚类。
估计种族对通过HCA维度介导的治疗的总的、直接的和间接的影响。我们
初步研究表明某些研究不足的维度(例如,可接受性)可能超过其他
尺寸(例如,在确定护理质量方面。此外,各种HCA的影响
尺寸可以根据种族而变化。通过分析黑人和白色患者的高质量多级数据集,
我们可以充分描述种族差异的性质,评估种族差异的相对重要性,
障碍,并确定种族特定的可改变的因素。我们的研究将提供新颖的,经验的,
关于HCA维度对OC结果的独特和集体影响的概括性见解。
这些见解将有助于确定和优先考虑特定的可修改因素,然后可以针对性地减少
并改善对所有患者的护理。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tomi F Akinyemiju其他文献
Adapting Enhanced Recovery After Surgery (ERAS) Protocols to Promote Equity in Cancer Care and Outcomes
调整加速康复外科 (ERAS) 方案以促进癌症护理和结果的公平
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:0
- 作者:
Clare Meernik;Michaela Z. Kolarova;Melina Ksor;Samantha Kaplan;Julie K. Marosky Thacker;Rebecca A. Previs;Tomi F Akinyemiju - 通讯作者:
Tomi F Akinyemiju
Neighborhood-level socioeconomic disparities in Radon testing in North Carolina from 2010 to 2020.
2010 年至 2020 年北卡罗来纳州氡气测试中社区层面的社会经济差异。
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:2.3
- 作者:
Zhenchun Yang;Lauren Prox;Clare Meernik;Yadurshini Raveendran;Phillip Gibson;Amie Koch;Jeffrey Clarke;Ruoxue Chen;J. Zhang;Tomi F Akinyemiju - 通讯作者:
Tomi F Akinyemiju
Tomi F Akinyemiju的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tomi F Akinyemiju', 18)}}的其他基金
Systemic Racism and Biological Embodiment of Risk in Breast Cancer Mortality
系统性种族主义和乳腺癌死亡率风险的生物学体现
- 批准号:
10453878 - 财政年份:2022
- 资助金额:
$ 49.46万 - 项目类别:
Systemic Racism and Biological Embodiment of Risk in Breast Cancer Mortality
系统性种族主义和乳腺癌死亡率风险的生物学体现
- 批准号:
10709512 - 财政年份:2022
- 资助金额:
$ 49.46万 - 项目类别:
Stress-related inflammation and racial disparities in ovarian cancer
卵巢癌中与压力相关的炎症和种族差异
- 批准号:
10064445 - 财政年份:2020
- 资助金额:
$ 49.46万 - 项目类别:
A Role of Multilevel Healthcare Access Dimensions in Ovarian Cancer Disparities
多层次医疗保健获取维度在卵巢癌差异中的作用
- 批准号:
9904903 - 财政年份:2019
- 资助金额:
$ 49.46万 - 项目类别:
Racial/ethnic differences in functional metabolites among ovarian cancer patients
卵巢癌患者功能代谢物的种族/民族差异
- 批准号:
10531800 - 财政年份:2019
- 资助金额:
$ 49.46万 - 项目类别:
A Role of Multilevel Healthcare Access Dimensions in Ovarian Cancer Disparities
多层次医疗保健获取维度在卵巢癌差异中的作用
- 批准号:
10614420 - 财政年份:2019
- 资助金额:
$ 49.46万 - 项目类别:
Metabolic Syndrome and Epigenetic Markers of Breast Cancer in Nigerian Women
尼日利亚女性乳腺癌的代谢综合征和表观遗传标志物
- 批准号:
9555400 - 财政年份:2016
- 资助金额:
$ 49.46万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 49.46万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 49.46万 - 项目类别:
Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 49.46万 - 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 49.46万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 49.46万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 49.46万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 49.46万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 49.46万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 49.46万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 49.46万 - 项目类别: